An empowered, clinically viable hematopoietic stem cell gene therapy for the treatment of multisystemic mucopolysaccharidosis type II
Molecular Therapy · 2024
DOI: 10.1016/j.ymthe.2024.01.034 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy, 2024. Verfasst von Sabyasachi Das und 16 weiteren Autor:innen. Beteiligte Einrichtung: Gene Therapy Program, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA 02115, USA. Hauptthemen laut MEDLINE: Mucopolysaccharidosis II, Iduronate Sulfatase. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Medizinischen Hochschule Hannover.
Abstract (Originalsprache)
Mucopolysaccharidosis type II (MPS II), or Hunter syndrome, is a rare X-linked recessive lysosomal storage disorder due to a mutation in the lysosomal enzyme iduronate-2-sulfatase (IDS) gene. IDS deficiency leads to a progressive, multisystem accumulation of glycosaminoglycans (GAGs) and results in central nervous system (CNS) manifestations in the severe form. We developed up to clinical readiness a new hematopoietic stem cell (HSC) gene therapy approach for MPS II that benefits from a novel highly effective transduction protocol. We first provided proof of concept of efficacy of our approach aimed at enhanced IDS enzyme delivery to the CNS in a murine study of immediate translational value, employing a lentiviral vector (LV) encoding a codon-optimized human IDS cDNA. Then the therapeutic LV was tested for its ability to efficiently and safely transduce bona fide human HSCs in clinically relevant conditions according to a standard vs. a novel protocol that demonstrated superior ability to transduce bona fide long-term repopulating HSCs. Overall, these results provide strong proof of concept for the clinical translation of this approach for the treatment of Hunter syndrome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gene Therapy Program, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA 02115, USA.
- Division of Hematology, Oncology and Stem Cell Transplantation, Department of Women and Child's Health, University of Padua, 35128 Padua, Italy.
- Genethon, 91000 Evry, France.
- AGC Biologics, 20091 Milan, Italy.
- Altheia Science s.r.l., 20122 Milan, Italy.
- Humanitas University and IRCCS Humanitas Research Hospital, 20090 Pieve Emanuele (MI), Italy.
Förderung
- Medizinischen Hochschule Hannover
Zitieren
APA
Das, S., Rruga, F., Montepeloso, A., Dimartino, A., Spadini, S., Corre, G., Patel, J., Cavalca, E., Ferro, F., Gatti, A., Milazzo, R., Galy, A., Politi, L. S., Rizzardi, G. P., Vallanti, G., Poletti, V., & Biffi, A. (2024). An empowered, clinically viable hematopoietic stem cell gene therapy for the treatment of multisystemic mucopolysaccharidosis type II. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2024.01.034
Vancouver
Das S, Rruga F, Montepeloso A, Dimartino A, Spadini S, Corre G, et al. An empowered, clinically viable hematopoietic stem cell gene therapy for the treatment of multisystemic mucopolysaccharidosis type II. Molecular Therapy. 2024. doi:10.1016/j.ymthe.2024.01.034
BibTeX
@article{Das2024,
author = {Das, Sabyasachi and Rruga, Fatlum and Montepeloso, Annita and Dimartino, Agnese and Spadini, Silvia and Corre, Guillaume and Patel, Janki and Cavalca, Eleonora and Ferro, Francesca and Gatti, Alessandra and Milazzo, Rita and Galy, Anne and Politi, Letterio S and Rizzardi, Gian Paolo and Vallanti, Giuliana and Poletti, Valentina and Biffi, Alessandra},
title = {An empowered, clinically viable hematopoietic stem cell gene therapy for the treatment of multisystemic mucopolysaccharidosis type II},
journal = {Molecular Therapy},
year = {2024},
doi = {10.1016/j.ymthe.2024.01.034}
}
EUVIMED